Regeneron reported Q4 2024 earnings today and declared its first-ever dividend of $0.88 per quarter. Click here to know what ...

Sales of Eylea, which the company co-developed with Bayer (DE:BAYA), rose 2% to $1.495 billion. Sales of the higher-dose, longer-lasting formulation Eylea HD rose 148% to $305 million in the U.S., ...

Moments after Regeneron CEO Len Schleifer scolded analysts for asking too many questions about the disappointing sales of eye ...

Piper Sandler adjusted its price target for Regeneron Pharmaceuticals (NASDAQ:REGN) shares, reducing it from the previous $1,195.00 to $1,013.00. Despite this change, the firm maintained its ...

IA: <10% body surface area involved, flat or slightly raised skin lesions; no skin tumors, no lymph nodes or visceral involvement IB: >10% body surface area involved, otherwise same as IB IIA ...

as well as to rule out primary cutaneous squamous cell carcinoma or metastasis from second squamous cell carcinoma from other sites. Our case also underscores the importance of performing a prompt ...

Copyright: © 2024 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.

In this report, we present the largest case series of patients developing AK and/or cutaneous SCC during therapy with sorafenib. The mechanism through which sorafenib may be implicated in the ...

It's officially that time of the year: our skin is itchy, scaly, and more closely resembles a lizard than a dewy, glazed donut. You likely have a dozen barrier-repairing lip balms and thick hand ...

However, Regeneron recently announced that its PD-1 inhibitor LIBTAYO had met its primary endpoint among patients with high risk cutaneous squamous cell carcinoma (CSCC). This positive news in ...

“At the first prespecified interim analysis, Libtayo achieved a remarkably high bar in improving disease-free survival in high-risk cutaneous squamous cell carcinoma. With no currently approved ...